|1.||Marbán, Eduardo: 22 articles (08/2015 - 02/2007)|
|2.||Cheng, Ke: 13 articles (08/2015 - 03/2012)|
|3.||Malliaras, Konstantinos: 10 articles (03/2015 - 01/2011)|
|4.||Sun, Baiming: 9 articles (08/2015 - 03/2012)|
|5.||Smith, Rachel R: 8 articles (03/2015 - 05/2008)|
|6.||Marbán, Linda: 8 articles (03/2015 - 03/2012)|
|7.||Terrovitis, John: 7 articles (03/2012 - 05/2008)|
|8.||Li, Tao-Sheng: 6 articles (08/2015 - 03/2010)|
|9.||Smith, Rachel Ruckdeschel: 6 articles (02/2014 - 02/2007)|
|10.||Tseliou, Eleni: 5 articles (08/2015 - 02/2013)|
10/01/2014 - "Here, we show, surprisingly, that c-kit expression has no relationship to CDCs' therapeutic efficacy in humans, and depletion of c-kit(+) cells does not undermine the structural and functional benefits of CDCs in a mouse model of myocardial infarction (MI). "
03/10/2012 - "We show intracoronary infusion of autologous CDCs after myocardial infarction is safe, warranting the expansion of such therapy to phase 2 study. "
03/01/2015 - "We tested CDCs as adjunctive therapy to reperfusion in a porcine model of myocardial infarction. "
03/01/2015 - "However, intracoronary delivery of CDCs after reperfusion in acute myocardial infarction has never been assessed in a clinically-relevant large animal model. "
01/01/2013 - "CDCs have been tested safely in an initial phase-1 clinical trial in patients after myocardial infarction. "
10/15/2011 - "Moreover, DC transfer studies revealed that merocytic cDCs and CD8α(+) cDCs were most susceptible to pDC help and subsequently promoted tumor-free survival in a therapeutic setting. "
02/01/2010 - "Adoptive transfer studies show that bone marrow pre-cDCs migrate from blood into the tumor where they generate cDCs. "
02/01/2010 - "In this study, we show that pre-cDCs are precursors for cDCs in tumors. "
12/01/2015 - "We emphasize that although fDCs could probably be applied as an alternative to cDCs for cancer therapy, the fDC protocol should not be applied to donors whose DCs acquire tolerogenic capabilities."
09/29/2015 - "Gene expression alterations in samples with high ATAD2 expression revealed upregulation of several cancer-related genes (B-MYB, CDCs, E2Fs) and gene sets that previously have been linked to aggressive disease and potential for new targeting therapies. "
|3.||Choledochal Cyst (Choledochal Cysts)
07/01/2013 - "The aim of this study was to compare the efficacy of single-incision laparoscopic hepaticojejunostomy (SILH) with that of conventional laparoscopic hepaticojejunostomy (CLH) for children with choledochal cysts (CDCs). "
07/01/2013 - "This study presents our 11-year surgical experience with choledochal cysts (CDC), focusing on the complexity in the diagnosis and management of large-size CDCs. "
10/01/2006 - "The purpose of this analysis is to study the clinical features, liver histology and the outcome after surgery in infants with choledochal cysts (CDCs), and to draw conclusions on the management strategy accordingly. "
10/01/2014 - "Choledochal cysts (CDCs) are believed to represent a risk factor for the development of neoplasia. "
03/01/2012 - "Choledochal cysts (CDCs) are increasingly being diagnosed antenatally. "
02/01/2014 - "It is unknown whether CDCs derived from advanced heart failure (HF) patients retain the same regenerative potency. "
04/01/2014 - "Cardiac progenitor cells (CPCs) isolated as cardiospheres (CSs) and CS-derived cells (CDCs) are a promising tool for cardiac cell therapy in heart failure patients, having CDCs already been used in a phase I/II clinical trial. "
04/01/2015 - "Our aim was to characterize the potency of pediatric CDCs derived from normal functioning myocardium of control heart disease (CHD) patients to those generated from age-matched end stage heart failure (ESHF) patients and to determine the mechanisms involved. "
03/21/2015 - "The ability to impact favourably on disease progression in non-ischaemic heart failure heralds new potential therapeutic applications of CDCs."
05/01/2008 - "Cardiosphere-derived resident cardiac stem cells (CDCs) are readily isolated from adult hearts and confer functional benefit in animal models of heart failure. "
12/24/2013 - "MRI revealed that allogeneic CDCs attenuated remodeling, improved global and regional function, decreased scar size, and increased viable myocardium compared with placebo 2 months post-treatment. "
02/01/2014 - "CDC-secreted SDF-1 levels correlated with decreases in scar mass over time in CADUCEUS patients treated with autologous CDCs. "
03/10/2012 - "Compared with controls at 6 months, MRI analysis of patients treated with CDCs showed reductions in scar mass (p=0·001), increases in viable heart mass (p=0·01) and regional contractility (p=0·02), and regional systolic wall thickening (p=0·015). "
02/01/2014 - "Injection of HF CDCs led to the greatest therapeutic benefit in mice, with the highest left ventricular ejection fraction, thickest infarct wall, most viable tissue, and least scar 3 weeks after treatment. "
03/10/2012 - "Cardiosphere-derived cells (CDCs) reduce scarring after myocardial infarction, increase viable myocardium, and boost cardiac function in preclinical models. "
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||Hepatocyte Growth Factor (Growth Factor, Hepatocyte)
|3.||Tissue Therapy (Cell Therapy)
|4.||Transplantation (Transplant Recipients)